BTKi

• Business
• Education
• Germany
• Healthcare
• Industrial
• Management
• News
• Pharma & Biotech
• Science

Merck’s Evobrutinib Shows Long-Term Efficacy and Improved Quality of Life in Multiple Sclerosis Patients, Revealing Potential RMS Treatment Advancements

(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The…